Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 11/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579395 | 0.88 | SLC6A7 (0.55) | SLC6A7SLC6A3MALT1PDE4APDE4B | |
| SCHEMBL4232284 | 0.85 | SLC6A7 (0.53) | SLC6A7SLC6A3MALT1KDM4EMEN1 | |
| SCHEMBL3585483 | 0.85 | SLC6A7 (0.52) | SLC6A7SLC6A3MALT1KDM4EMEN1 | |
| SCHEMBL30674402 | 0.84 | SLC6A7 (0.68) | SLC6A7SLC6A3MALT1KDM4E | |
| SCHEMBL1135093 | 0.84 | SLC6A7 (0.68) | SLC6A7SLC6A3MALT1KDM4E | |
| SCHEMBL4238999 | 0.84 | SLC6A7 (0.51) | SLC6A7SLC6A3MALT1KDM4EMEN1 | |
| SCHEMBL3579486 | 0.83 | SLC6A7 (0.50) | SLC6A7SLC6A3MALT1PDE4APDE4B | |
| SCHEMBL3814544 | 0.80 | KDM4E (0.52) | SLC6A7SLC6A3MALT1KDM4ECYP2C19 | |
| SCHEMBL3811164 | 0.80 | KDM4E (0.51) | MALT1KDM4ECYP2C19MEN1KMT2A | |
| SCHEMBL3812149 | 0.78 | KDM4E (0.54) | SLC6A7SLC6A3MALT1KDM4ECYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286820-A1 | (R)-PHENYL(HETEROCYCLE)METHANOL-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2009-11-19 | — | — | US | disclosed |
| EP-2089376-A1 | (R)-PHENYL(HETEROCYCLE)METHANOL-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2084145-A2 | (S)-PHENYL(HETEROCYCLE)METHANOL-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090181992-A1 | (S)-PHENYL(HETEROCYCLE)METHANOL-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20080146596-A1 | (R)-PHENYL(HETEROCYCLE)METHANOL-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080146600-A1 | (S)-PHENYL(HETEROCYCLE)METHANOL-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2008067120-A2 | (S)-PHENYL(HETEROCYCLE)METHANOL-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008058068-A1 | (R)-PHENYL(HETEROCYCLE)METHANOL-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146600-A1 | (S)-PHENYL(HETEROCYCLE)METHANOL-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | CYP11B2, SDHA, CYCS | SLC6A7 1681/4885SLC6A3 1333/4885MALT1 1399/4885 |
| US-20090181992-A1 | (S)-PHENYL(HETEROCYCLE)METHANOL-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | APP, PARK7, BACE1 | SLC6A7 1297/4885SLC6A3 80/4885MALT1 2162/4885 |
| US-20080146596-A1 | (R)-PHENYL(HETEROCYCLE)METHANOL-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | CYP11B2, CYP11B1, CYP3A7 | SLC6A7 2041/4885SLC6A3 1701/4885MALT1 1044/4885 |
| US-20090286820-A1 | (R)-PHENYL(HETEROCYCLE)METHANOL-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | CYP11B2, CYP11B1, CYP3A7 | SLC6A7 2041/4885SLC6A3 1701/4885MALT1 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.